Supportive evidence from poorly controlled or uncontrolled studies Conflicting evidence with the weight of evidence supporting the recommendation
Expert consensus or clinical experience
Diabetes Mellitus (GDM) IV. Prevention/Delay of Type 2 Diabetes V. Diabetes Care VI. Prevention and Management of Diabetes
Complications VII. Diabetes Care in Specific Populations VIII. Diabetes Care in Specific Settings IX. Strategies for Improving Diabetes Care
ADA. Diabetes Care 2011;34(suppl 1):S12. Table 1.
I. CLASSIFICATION AND DIAGNOSIS OF DIABETES
Classification of Diabetes
• Type 1 diabetes
– β-cell destruction
Clear or supportive evidence from adequately powered well-conducted, generalizable, randomized controlled trials
Compelling nonexperimental evidence
Supportive evidence from well-conducted cohort studies or case-control study
2011年ADA糖尿病诊疗指南( 最新,完整,s
Section
ADA Evidence Grading System of Clinical Recommendations I. Classification and Diagnosis of Diabetes II. Testing for Diabetes in Asymptomatic Patients III. Detection and Diagnosis of Gestational
• Gestational diabetes mellitus
ADA. I. Classification and Diagnosis. Diabetes Care 2011;34(suppl 1):S12.
Criteria for the Diagnosis of Diabetes
A1C ≥6.5%
*In the absence of unequivocal hyperglycemia, result should be confirmed by repeat testing. ADA. I. Classification and Diagnosis. Diabetes Care 2011;34(suppl 1):S13. Table 2.
Slide No.
3 4-11 12-15 16-19 20-21 22-50 51-101 102-119 120-126 127-130
ADA Evidence Grading System for Clinical Recommendations
Level of Evidence
A
B C
E
Description
ADA. I. Classification and Diagnosis. Diabetes Care 2011;34(suppl 1):S13. Table 2.
Criteria for the Diagnosis of Diabetes
A1C ≥6.5% The test should be performed in a laboratory using an NGSP-certified method standardized to the DCCT assay*
Criteria for the Diagnosis of Diabetes
Criteria for the Diagnosis of Diabetes
Fasting plasma glucose (FPG) ≥126 mg/dl (7.0 mmol/l)
Fasting: no caloric intake for at least 8 h*
*In the absence of unequivocal hyperglycemia, result should be confirmed by repeat testing. ADA. I. Classification and Diagnosis. Diabetes Care 2011;34(suppl 1):S13. Table 2.
OR
Fasting plasma glucose (FPG) ≥126 mg/dl (7.0 mmol/l)
OR
Two-hour plasma glucose ≥200 mg/dl (11.1 mmol/l) during an OGTT
OR
A random plasma glucose ≥200 mg/dl (11.1 mmol/l)
• Type 2 diabetes
– Progressive insulin secretory defect
• Other specific types of diabetes
– Genetic defects in β-cell function, insulin action – Diseases of the exocrine pancreas – Drug- or chemical-induced